Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.

ABSTRACT:

Aims

LIK066 (licogliflozin) is a dual sodium glucose co-transporter 1/2 inhibitor with potential benefits in weight loss. This study evaluated the efficacy, tolerability and safety of licogliflozin in Japanese adults with obesity.

Materials and methods

This study was a randomized, double-blind, placebo-controlled, dose-finding study to evaluate the effect of licogliflozin (2.5, 10, 25 and 50 mg once daily) in 126 Japanese patients with obesity. The primary objective was to examine the dose-response relationship of licogliflozin treatment in body weight reduction relative to placebo at 12 weeks. The secondary objectives included assessment of responder rates, change in parameters related to complications, visceral and subcutaneous fat area, and safety during 12 weeks of treat

SUBMITTER: Yokote K 

PROVIDER: S-EPMC9328287 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature